Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.74 |
| ▸ | CTSB | P07858 | 4/20 | 0.74 |
| ▸ | CTSL | P07711 | 4/20 | 0.74 |
| ▸ | CTSK | P43235 | 2/20 | 0.74 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CTSH | P09668 | 1/20 | 0.74 |
| ▸ | CTSS | P25774 | 1/20 | 0.74 |
| ▸ | CTSC | P53634 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | CTSG | P08311 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-64 SCHEMBL13283063 | 1.00 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL23132676 | 1.00 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL13523481 | 1.00 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL16452857 | 1.00 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL7087294 | 1.00 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| E-64 SCHEMBL32663599 | 0.99 | CAPN1 (0.73) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11067480 | 0.88 | CAPN1 (0.74) | CAPN1CTSBCTSLCTSKCAPN9 | |
| Agmatine SCHEMBL18784085 | 0.88 | CAPN1 (0.59) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11184932 | 0.87 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 | |
| SCHEMBL11188762 | 0.87 | CAPN1 (0.72) | CAPN1CTSBCTSLCTSKCAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338529-A1 | COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-11547708-B2 | Compositions and methods to protect mammalian tissue against cold and other metabolic stresses | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2023-01-10 | — | — | US | disclosed |
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| EP-2811999-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20200368230-A1 | COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-11-26 | — | — | US | disclosed |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| WO-2019040359-A1 | COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2016037157-A2 | TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-10 | — | — | WO | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8013014-B2 | Aza-peptide epoxides | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013014-B2 | Aza-peptide epoxides | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080213252-A1 | METHODS OF TREATING ITCH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-04 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008086069-A1 | METHODS OF TREATING ITCH | THE GENERAL HOSPITAL CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007041775-A1 | CYSTEINE PROTEASE INHIBITORS INCORPORATING AZIDE GROUPS | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-04-19 | — | — | WO | disclosed |
| US-20040042961-A1 | Development of an in vivo functional assay for proteases | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | CAPN9, CAPNS1, CAPN2 | CAPN1 4/4885CTSB 367/4885CTSL 1444/4885 |
| US-20200368230-A1 | COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES | TXN2, HSPA9, TXNRD2 | CAPN1 567/4885CTSB 156/4885CTSL 246/4885 |
| US-11547708-B2 | Compositions and methods to protect mammalian tissue against cold and other metabolic stresses | TXN2, HSPA9, TXNRD2 | CAPN1 567/4885CTSB 156/4885CTSL 246/4885 |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | ACE2, ACE, SARS1 | CAPN1 569/4885CTSB 31/4885CTSL 6/4885 |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSB 8/4885CTSL 21/4885 |
| US-20230338529-A1 | COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE | MMP1, MMP13, MMP3 | CAPN1 235/4885CTSB 8/4885CTSL 100/4885 |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | SERPINB1, EPHX1, EPX | CAPN1 199/4885CTSB 74/4885CTSL 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.